€10M investment boosts Finnish capabilities in cancer immunotherapy
Cancer IO is a new cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland’s Personalized Health Program.
This University of Helsinki coordinated project integrates immuno-oncology (IO) activities at the Universities of Helsinki and Turku, 3 University hospitals and one central hospital, 8 Finnish small or medium enterprises, several cancer patient organizations and the 9 largest IO-investing pharmaceutical companies. With a total funding of 10 million euros, Cancer IO is a significant IO focused Nordic research and innovation program.
Read the press release on the University of Helsinki website
Newsweek
